Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis

• by Stephen Weidinger, Kristian Reich, Naiem Issa, H. Chih-ho Hong, Christopher G. Bunick, Pinaki Biswas, Gary Chan, Erman Güler, Melissa Watkins, Justine Alderfer

• June 27, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases

• by Bingrun Li, Xiaoting Song, Cunhao Shan, Junchen He, Zihan Wang, Katarina Stevanovic, Torsten Zuberbier, Zuotao Zhao, Litao Zhang

• June 18, 2026

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management

• by Romagnuolo, Maurizio , Crovella, Sergio , Abou-Saleh, Haissam , Moltrasio, Chiara

• May 11, 2026